Seres Therapeutics: VOWST’s Time To Shine (NASDAQ:MCRB)

Clostridium difficile is a type of bacteria that causes colitis, a severe inflammation of the colon.

Ozgu Arslan

Seres Therapeutics (NASDAQ:MCRB) is a small ($615 million market cap) commercial-stage company developing microbiome therapeutics (Figure 1) for serious diseases. On June 5, Seres and 50-50 partner Nestlé (OTCPK:NSRGY) launched VOWST (live fecal microbiota spores), the first

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *